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Introduction: Achievement and maintenance of good asthma control is a major objective in
asthma management. However, asthma control in many patients is suboptimal, due to
improper use of asthma medications and non-adherence. The aim of this study was to evaluate
the effect of a pharmacist intervention on asthma control in adult patients.
Methods: A 6-month cluster randomized controlled trial was undertaken with allocation of
community pharmacies to intervention or control group. Adult asthma patients in the interven-
tion group received a protocol-based intervention addressing individual needs related to
asthma control, inhaler technique and medication adherence. Patients in the control group
received usual care. Main variables were measured at baseline, 3 and 6 months.
Results: 336 patients completed the study, 150 in the control group and 186 in the intervention
group. The intervention resulted in enhanced asthma control: Patients receiving the interven-
tion had an Odds ratio of 3.06 (95% CI:1.63e5.73; p < 0.001) of having controlled asthma six
months later. In the intervention group mean ACQ scores significantly improved [0.66 points
(SD: 0.78); p < 0.001] and the number of controlled asthma patients increased by 30.1%
(p < 0.001) after 6 months. The intervention also resulted in improved medication adherence
(by 40.3%, p < 0.001) and inhaler technique (by 56.2%, p < 0.001). No significant changes for
any of these variables were observed in the control group.34 958 249584.
om, mavigc@correo.ugr.es (V. Garcı´a-Ca´rdenas).
3 Elsevier Ltd. All rights reserved.
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A pharmacist intervention on asthma control 1347Conclusion: The AFasma study focused on the important outcomes of asthma management,
and showed that through the designed intervention, community pharmacists can increase
controlled asthma patients compared to usual care. Trial registration NCT01085474.
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In 2006 a new asthma management approach was adopted
by the Global Initiative for Asthma (GINA) signalling an
important change of philosophy based on asthma control
rather than asthma severity or symptoms [1]. Since then,
good asthma control has become a primary objective in the
management of asthma patients [2], that is an absence of
daily symptoms and exacerbations, minimisation of lung
function variability or no impairment of quality of life.
However, asthma control in many patients is sub-optimal
[3,4], with negative implications for the patient’s health,
quality of life and/or health care costs. Reasons for this
poor asthma control are complex including clinical and
behavioral issues, such as co-morbidity, ineffective delivery
of treatment, low adherence and/or ongoing exposure to
triggers [5] among others.
Adherence to preventer medications represents a major
challenge [6] since non-adherence to inhaled therapy is
common among asthma patients due to intentional or unin-
tentional causes [7]. Despite correct inhaler technique being
essential for effective drug delivery, a literature review
found that misuse of inhaler devices is frequent in practice
[8] contributing to poor asthma control [9e12]. Hence
updated asthma guidelines [2,13] highlight the importance
of implementing strategies aimed at improving patients’
knowledge, skills and aptitudes to self-manage their asthma.
A literature review [14] revealed an increase of phar-
macists’ participation in outcome-based asthma manage-
ment programs, with positive impact in symptoms [15e21],
pulmonary function [16e23] or severity [16,22e24]. At the
time this study was undertaken only one other intervention
study [25] in a community pharmacy setting had applied the
new asthma management “control” approach. Results
showed a positive impact on asthma control only in a sub-
group of uncontrolled patients at baseline, suggesting that
the impact of a community pharmacist’s intervention on
asthma control had yet to be established. An additional
recently published study in 2012 has found significant im-
provements in asthma control for patients receiving a
pharmacy asthma service during 6 months of follow-up [26].
The objective of the present trial (AFasma study) was to
evaluate whether a pharmacist intervention focused on
asthma control, medication adherence and inhaler tech-
nique would result in an improved asthma control in adult
asthma patients.Methods
Study design
This study was a 6-month cluster randomized controlled trial
undertaken between November 2010 and June 2011 in Spain.Patients
Patients were recruited consecutively in the participant
pharmacies (recruitment period: NovembereDecember
2010). To be eligible, patients were required to have been
prescribed Symbicort (Budesonide/Formeterol, AstraZe-
neca) for their own use. Inclusion criteria were: aged
18 years or older and have a physician’s diagnosis of
asthma. Exclusion criteria included: participation in
another asthma education program, pregnancy, presence of
communication difficulties, suffering from seasonal asthma
(asthma symptoms that only occurred in a seasonal pattern)
or other pathologies such as Chronic Obstructive Pulmonary
Disease, emphysema, lung cancer, respiratory infection and
terminal illness (considered as any disease that was
reasonably expected to result in the death of the patient).
Sample size was calculated to detect a difference in
asthma control of greater than or equal to 20% between
study groups. We applied a two-tailed test for comparing
two binominal proportions, considering a type II error of
20% (bZ 0.80) and 95% significance (pZ 0.05). Sample size
was adjusted according to standard criteria for cluster
randomized trials, using a design effect (DE) of 1.45. The DE
was calculated as follows: DEZ 1 þ (nc  1)*ICC (Where nc
is the mean number of individuals in the cluster and ICC the
intra-cluster correlation coefficient). The ICC in the present
work was considered to be 0.05, and the mean cluster size
was assumed to be 10 patients [27]. A potential loss of 20%
was estimated. Therefore, a minimum of 342 patients and
35 pharmacies were required.
All community pharmacies in the province of Malaga and
all members of the Spanish Society of Community Pharmacy
in the province of Madrid were invited by letter, with all
responders enrolled.
Pharmacies were the unit of randomization and were
assigned by an independent researcher after they agreed
to participate in the study to either intervention (IG) or
control group (CG) using a computer-generated list of
random numbers with ratio 1:1. Cluster-randomization was
used to minimize cross-contamination. Given the nature of
the intervention pharmacists or patients could not be
blinded.
Outcome measures
Asthma control was the primary outcome and was assessed
using the Asthma Control Questionnaire (ACQ; 5 item
version, Spanish) [28,29]. ACQ was self-completed by the
patient and the pharmacist calculated the mean of 5 items
scored on a 7-point interval scale. For statistical purposes
this variable was dichotomized into well-controlled (ACQ
score  0.75) and uncontrolled/partly controlled (ACQ
score > 0.75) [30]. A decrease of 0.5 points on the patient’s
ACQ punctuation was considered clinically relevant [29].
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medication adherence. Inhaler technique was assessed by
the pharmacist using a 10-step turbuhaler checklist
consistent with the Spanish Guide for Asthma Management-
Guide for Asthma Educators (GEMA-Educators) [13]. The
patient was asked to perform the inhaler technique with a
placebo device in front of the pharmacist. Patients who
performed all the checklist steps correctly were classified
as having correct inhaler technique. Asthma medication
adherence was assessed using the 4-item Moriskye
GreeneLevine scale [31], which allows the patient to be
classified as adherent or non-adherent.
Primary and secondary outcomes were measured at
baseline (initial visit), 3 months (intermediate visit) and 6
months (final visit). Demographic variables and other vari-
ables related to asthma control were recorded and used for
adjustment in the statistical analysis.
Pharmacist training
33 pharmacists allocated to the IG attended a one-day
workshop. They were trained to provide education on
asthma control, medication adherence and inhaler tech-
nique by a respiratory physician and a pharmacist
educator/researcher. Training on the study protocol and
documentation forms was also delivered. All pharmacists
received the Spanish Guide for Asthma Management (GEMA
2009) [32] and the GEMA-Educators [13].
In addition to the training, pharmacists were assisted by
a facilitator through regular visits to the pharmacies, to
check for compliance with the protocol and solve any
problem or query during the study [33]. Counseling via
email and phone was also offered.
32 Pharmacists allocated in the CG received instructions
by phone about the study protocol before the beginning of
the study and were monitored through 2 visits to the
pharmacy.
Pharmacist-patient intervention
During the 6 months of follow-up, patients attended 3
scheduled visits to the pharmacy. However, additional visits
(up to 6) to intervention patients could be provided if
needed. Patient’s demographic details were collected in
the initial visit and an individualized patient needs analysis
on asthma control, medication adherence and inhaler
technique was conducted at every visit by the pharmacist in
a private counseling area. Control patients received no
intervention other than the pharmacist’s usual care (nor-
mally the safe supply of medicines and medication-taking
advice to the patient), whereas patients enrolled in the IG
received a protocol based intervention based on GEMA
recommendations. Patients were educated using verbal
instructions, physical demonstration and written informa-
tion about turbuhaler use. When appropriate the type of
non-adherence (intentional or unintentional) and causes of
intentional non-adherence were explored with the Beliefs
about Medicines Questionnaire and Health Beliefs Model
[34]. Several aspects of asthma control were also covered
in each visit. Finally pharmacist and patient jointly agreed
goals for the next visit.Approval for the study was given by the Ethics and
Research Committee of the Virgen de las Nieves University
Hospital. A written information sheet was provided and
informed consent was obtained.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
15.0 (SPSS Inc, Chicago, Illinois, USA) and SAS 9.3 (SAS
Institute, 2011). A p-value < 0.05 was considered to indi-
cate statistical significance.
Quantitative variables were expressed as the mean SD
and categorical variables were expressed as frequency and
percentages. To compare quantitative variables, Student’s
t-test for independent samples and Student’s t-test for
paired samples were used. Chi-square analysis was per-
formed for comparisons between groups at baseline and
study completion. McNemar test was performed before and
after intragroup comparisons to further measure categori-
cal variables.
ACQ scores through the study visits were analysed using
a repeated measures multivariate ANOVA. To compare
changes on ACQ means through the visits between the study
groups, covariance analysis (ANCOVA) was performed, using
the study group as the principal effect and baseline ACQ
scores as co-variable. A sub-analysis of the effect of the
intervention based on asthma control at baseline was also
performed.
It is recommended that the analysis of cluster rando-
mised trials takes account of clustering, even where the ICC
is small [35]. The regression analysis of the primary
outcome used the mixed model approach recommended by
Murray [35]. However, accounting for clustering had little
impact on estimates or precision, possibly because of the
extremely small ICC and small number of patients per
pharmacy. Consequently, analysis of the secondary out-
comes (deemed to be part of the causal pathway to the
primary endpoint) used simpler methods which assumed no
clustering by pharmacy.
A multivariate logistic regression analysis was performed
to explore the association between asthma control and
study group; estimation was by maximum likelihood using
the SAS GLIMMIX procedure. This analysis included a
random intercept for pharmacy nested within group to ac-
count for clustering of patients within pharmacies and was
adjusted by covariates that could affect asthma control
(Asthma control at baseline, gender, age, Body Mass Index,
smoking status, number of asthma drugs and living area).
This analysis was repeated using an intention to treat
approach (ITT) assuming a worst-case scenario (patients in
the CG ended with controlled asthma and patient in the IG
ended with uncontrolled asthma) for patients with missing
outcomes data.
Results
Study sample
Initially 65 pharmacies were enrolled, and after with-
drawals, 51 pharmacies (22 in the CG and 29 in the IG)
completed the study. 384 patients were offered to enter
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the study (160 in the CG and 186 in the IG). However one
pharmacy and its 10 patients were excluded from the
analysis due to lack of reliable data, leaving 50 pharmacies
(21 in the CG and 29 in the CG) and 336 patients analysed
(150 in the CG and 186 in the IG). There were 7 patients per
pharmacy on average ranging from 2 to 10. 107 out of 186
patients in the IG attended more than three times to the
pharmacy, and 51 (27.4%) completed 6 visits (Fig. 1).
Patients in both IG and CG had similar demographic and
clinical characteristics (Table 1). However percentage
of uncontrolled patients, mean number of anti-asthmaticFigure 1 Flowchart of patients and phdrugs and percentage of patients living in an urban area
were significantly higher in the IG (p Z 0.005, p Z 0.038
and p < 0.001 respectively).Primary outcome: asthma control
Mean ACQ scores significantly decreased from the initial to
the intermediate visit in both IG (0.32 points, SD: 0.91,
p < 0.001) and CG (0.16 points, SD: 0.73, pZ 0.017), while
between the intermediate visit and the final visit the
decrease was only observed in the IG (0.34 points, SD: 0.65,armacies during the AFasma study.
Table 1 Baseline characteristics of study patients.
Total (n Z 336) IG (n Z 186) CG (n Z 150) p Value
Primary variables
ACQ punctuation; mean (SD) 1.4 (1.1) 1.4 (1.1) 1.3 (1.2) 0.444
Controlled asthma; n (%) 116 (34.5) 52 (28.0) 64 (42.7) 0.005
Correct inhaler technique; n (%)a 72 (21.4) 36 (19.5) 36 (24.0) 0.302
Adherence to asthma treatment; n (%)b 130 (38.7) 71 (38.2) 59 (39.3) 0.828
Other variables
Male; n (%) 155 (46.1) 82 (44.1) 73 (48.7) 0.402
Age (years); mean (SD) 55.8 (19.1) 54.3 (19.1) 57.8 (19.0) 0.097
BMI (kg/m2); mean (SD) 27.1 (5.3) 27.0 (5.5) 27.2 (5.1) 0.676
Current smoker; n (%) 70 (20.8) 40 (21.5) 30 (20.0) 0.736
Urban living area; n (%) 242 (72.0) 112 (66.2) 130 (86.7) <0.001
Marital status (with partner); n (%) 185 (55.1) 98 (52.7) 87 (58.0) 0.331
Level of education
No education; n (%) 50 (14.9) 23 (12.4) 27 (18.1) 0.351
Primary; n (%) 123 (36.7) 66 (35.5) 57 (38.3)
Secondary/Vocational education; n (%) 86 (25.7) 52 (28.0) 34 (22.8)
University; n (%) 76 (22.7) 45 (24.2) 31 (20.8)
Employment status
Unpaid worker; n (%) 103 (30.7) 54 (29.0) 49 (32.7) 0.711
Paid worker; n (%) 112 (33.3) 65 (34.9) 47 (31.3)
Unemployed or retired person; n (%) 121 (36.0) 67 (36.0) 54 (36.0)
Anti-asthmatic drugs; mean (SD) 1.5 (0.7) 1.6 (0.7) 1.4 (0.7) 0.038
Type of controller treatment
Low-dose ICS plus long-acting b2 agonists 13 (3.9) 7 (3.8) 6 (4.0) 0.275
Medium-dose ICS plus long-acting b2 agonists 276 (82.1) 158 (84.9) 118 (78.7)
High-dose ICS plus long-acting b2 agonists 47 (14.0) 21 (11.3) 26 (17.3)
Use of other ICS; n (%) 8 (2.4) 5 (2.7) 3 (2.0) 0.681
Use of oral corticosteroids; n (%) 2 (0.6) 1 (0.5) 1 (0.7) 0.879
Use of anticholinergic drugs; n (%) 36 (10.7) 24 (12.9) 12 (8.0) 0.149
Use of antileukotriene drugs; n (%) 34 (10.1) 24 (12.9) 10 (6.7) 0.060
Use of short-acting b2 agonists; n (%) 99 (29.5) 59 (31.7) 40 (26.7) 0.312
CG: control group; IG: intervention group; SD: standard deviation; Kg: kilograms; m: meters; BMI: body mass index; ICS: inhaled
corticosteroids.
a Correct performance of all steps for Turbuhaler inhaler technique. 10-step Turbuhaler checklist.
b Morisky-Green-Levine test.
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0.66 (SD: 0.78, p < 0.001) in mean ACQ scores was observed
(Fig. 2).
In the IG, the proportion of patients with controlled
asthma significantly increased from baseline (28.0%, nZ 52)Figure 2 Mean ACQ scores across the study visits.to the intermediate visit (43.0%, n Z 80) and from the in-
termediate visit to the final visit (58.1%, nZ 108), while this
proportion in the CG remained similar (Fig. 3). At the end of
the study, asthma was controlled in significantly more pa-
tients in the IG than in the CG (58.1% versus 46.0%,
p Z 0.028), with an Odds Ratio of 3.06 (95% CI:1.63e5.73;Figure 3 Proportion of patients with controlled asthma across
the study visits.
A pharmacist intervention on asthma control 1351p < 0.001) (Table 2). The Intrapharmacy correlation coeffi-
cient was found to be very small (<0.001), signaling there
was no cluster effect. The results for the ITT approach,
where patients with missing outcomes were included (20 IG
and 5 CG) showed an adjusted odds ratio of 1.94 (95%
CI:1.06e3.55; p Z 0.032).Table 2 Multivariate logistic regression analysis to assess
the effect of pharmacist intervention on asthma control at
the endpoint (n Z 327, missing data on age and BMI of 9
patients).
Variable Adjusted OR 95%CI p Value
Group assignment
Control Reference
Intervention 3.059 1.632e5.733 <0.001
Sex
Female Reference
Male 1.254 0.724e2.173 0.418
Age
Older than 78 Reference
From 18 to 30 0.958 0.293e3.130 0.943
From 30 to 42 0.831 0.243e2.837 0.766
From 42 to 54 0.468 0.140e1.562 0.216
From 54 to 66 0.712 0.240e2.108 0.538
From 66 to 78 0.398 0.137e1.159 0.091
Smoking status
Non-smoker Reference
Smoker 0.859 0.429e1.719 0.0667
Living area
Urban Reference
Rural 1.386 0.746e2.574 0.301
BMI
Obese (BMI 
30 kg/m2)
Reference
Normal weight
(18.5  BMI 
24.99 kg/m2)
1.545 0.733e3.257 0.252
Overweight
(25  BMI 
29.99 kg/m2)
1.291 0.628e2.654 0.487
Number of anti-asthmatic drugs
Three or more Reference
One 0.902 0.378e2.147 0.814
Two 0.687 0.275e1.715 0.420
Asthma control at baseline
Controlled Reference
Uncontrolled 0.057 0.028e0.114 <0.001
OR: Odds Ratio; 95%CI: 95% confidence interval; BMI: body mass
index.
Raw data OR (simple logistic regression analysis): 1.625 (95%CI:
1.054e2.507; p Z 0.028).
Assuming mean values for age and BMI (nZ 336); OR: 3.117; IC:
1.669e5.823; p < 0.001.
Intention to treat (n Z 352); OR: 1.942; IC: 1.061e3.553;
p Z 0.032.
Intention to treat assuming mean values for age and BMI
(n Z 361); OR: 1.997; IC: 1.089e3.662; p Z 0.026.
HosmereLemeshow test (Chi-squared Z 6.038; p Z 0.643);
Nagelkerke R-squared: 0.407.A subgroup analysis of uncontrolled asthma patients at
baseline showed a greater effect of the intervention on
both proportion of controlled patients and mean ACQ scores
after 6 months of follow up compared to those patients that
were well-controlled at baseline (Table 3).
Secondary outcomes: inhaler technique and
medication adherence
Proportion of patients with incorrect performance of steps
for Turbuhaler inhaler technique at baseline is summarised
in Table 4.
The percentage of intervention patients with correct
inhaler technique significantly increased between baseline
(19.5%) and intermediate visit (57.0%, p < 0.001), and be-
tween intermediate visit and final visit (75.7%, p < 0.001).
Significant increase was also observed in patients included
in the CG between baseline (24.0%) and intermediate visit
(46.0%, p < 0.001), but not between intermediate visit and
final visit (50.0%, p Z 0.286). Proportion of patients with
correct inhaler technique at the end of the study was
significantly higher in the IG (75.8% versus 50.0%, p < 0.001)
(Fig. 4).
When compared with the CG, proportion of patients in
the IG who performed steps 2, 4, 6, 7, 8, and 10 of the
inhaler technique correctly was significantly higher at the
final visit (Table 5).
In the IG, proportion of patients adherent to asthma
treatment significantly increased from baseline (38.2%) to
intermediate visit (60.8%; p < 0.001), as well as between
intermediate visit and final visit (78.5%; p< 0.001). In the CG
this increase was observed between baseline (39.3%) and
intermediate visit (53.3%; p < 0.001), but not between in-
termediate visit and final visit (52.0%; pZ 0.839). Proportion
of adherent patients at the end of the study was significantly
higher in the IG (78.5% versus 52.0%, p < 0.001) (Fig. 5).
Discussion
The results show that the educational intervention in this 6-
month study significantly improved asthma control in pa-
tients allocated in the IG, compared to usual care. Sec-
ondary outcomes important for asthma management were
also improved, and the results remained significant when a
more restrictive ITT analysis was used.
Within the first 3 months of follow-up, a significant
improvement in ACQ scores, inhaler technique and medi-
cation adherence among patients in both study groups was
observed. These positive results in the CG could be attrib-
uted to several factors; patients may have modified their
behavior because they knew they were being studied
(Hawthorne effect) or because as part of the measurement
of the main variables, they were asked questions about
their asthma control, medication adherence and inhaler
technique, activities that may not usually have been per-
formed in the pharmacy. Additionally, even though control
pharmacists were asked not to change their usual care
during the study, they might have provided more informa-
tion than the one usually provided. Although community
pharmacists have specific medication and disease knowl-
edge, they usually demand and are provided additional
Table 3 Sub-analysis of the effect of the intervention based on asthma control at baseline.
Patients with controlled asthma
at baseline (n Z 116)a
Patients with uncontrolled asthma
at baseline (n Z 220)b
IG CG p-Value IG CG p-Value
Controlled asthma (final visit); n (%) 47 (90.4) 54 (84.4) 0.337 61 (45.5) 15 (17.4) <0.001
Correct Turbuhaler inhaler technique
(final visit); n (%)c
38 (73.1) 36 (56.3) 0.061 103 (76.9) 39 (45.3) <0.001
Difference between groups in adjusted
mean changes for ACQ from baseline
to intermediate visit; points (IC95%)c
0.05 (0.15e0.25) 0.634 0.21 (0.01e0.44) 0.065
Difference between groups in adjusted
mean changes for ACQ from baseline
to final visit; points (IC95%)c
0.18 (0.37e0.02) 0.079 0.62 [0.80 (0.43)] <0.001
CG: control group; IG: intervention group; 95%CI: 95% confidence interval.
a Intervention group (n Z 52), Control group (n Z 64).
b Intervention group (n Z 134), Control group (n Z 86).
c Analysis of covariance (ANCOVA), using the patient’s group assignment as the primary effect and baseline ACQ punctuation as the co-
variable (differences are expressed compared to the CG).
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ceutical care service. Intervention pharmacists were pro-
vided with training above and beyond the usual training a
pharmacist would receive on asthma management and so
that they could effectively address patients needs based on
asthma control, medication adherence and/or inhaler use.
However, it should be noted that these improvements were
sustained at 6 months only in intervention patients, sug-
gesting that to detect an impact in patient outcomes,
future similar research should be carried out during at least
that period of time.
Our overall findings agree with other published research
[15e24]. Two studies in a community pharmacy setting
[25,26] were found to measure asthma control as the pri-
mary outcome, reflecting the GINA 2006 shift of paradigm
in asthma management. Armour et al. [26] assessed asthma
control using a symptom/activity tool and the ACQ forTable 4 Proportion of patients with incorrect performance of s
Turbuhaler inhaler technique step Total
1 Unscrew and lift off the cover 9 (
2 Hold the inhaler upright 81 (
3 Twist the red grip fully to the right as far as it
will go and twist it back again to the left.
A “click” will be heard
41 (
4 Breathe out gently taking care not to breathe
into the Turbuhaler
157 (
5 Place mouthpiece between teeth and lips 52 (
6 Inhale forcefully and deeply 75 (
7 Remove the inhaler from the mouth, hold
breath for 8 s and exhale away from the
mouthpiece
140 (
8 If further doses are needed wait 30 s and
repeat steps from 2 to 7a
59 (
9 Replace white cap 22 (
10 Rinse mouth with water. Do not swallow 142 (
a This step was assessed in those patients prescribed with two conspatients receiving either a three- or four- visit asthma
pharmacy service. They found an increase in patients
classified as having good asthma control by 32% (for the
three-visit group) and by 38% (for the four-visit group) and a
mean decrease in ACQ scores of 0.57 and 0.56 respectively.
Similar results in both increase percentage of controlled
patients and mean decrease of ACQ scores were also found
in our study. Mehuys et al. [25] measured asthma control
with a clinically validated tool (Asthma Control Test, ACT)
and found that the intervention significantly improved ACT
scores only in a subgroup of patients having insufficiently
controlled asthma at baseline. However in the present
study, positive results were found not only in a subgroup of
uncontrolled patients at baseline but also in the aggregated
data. As previously suggested [9], this greater improvement
in asthma control on uncontrolled patients at baseline can
establish a different interventional approach in asthmateps for Turbuhaler inhaler technique at baseline.
(n Z 336) IG (n Z 186) CG (n Z 150) p Value
2.7) 2 (1.1) 7 (4.7) 0.043
24.1) 37 (19.9) 44 (29.3) 0.044
12.2) 26 (14.0) 15 (10.0) 0.268
46.7) 90 (48.4) 67 (44.7) 0.497
15.5) 27 (14.5) 25 (16.7) 0.588
22.3) 51 (27.4) 24 (16.0) 0.012
41.7) 86 (46.2) 54 (36.0) 0.058
50.0) 35 (53.0) 24 (46.2) 0.458
6.5) 15 (8.1) 7 (4.7) 0.211
42.3) 77 (41.4) 65 (43.3) 0.721
ecutive inhalations (118 patients: CG Z 52; IG Z 66).
Figure 4 Proportion of patients with correct inhaler tech-
nique across the study visits.
Figure 5 Proportion of adherent patients to asthma
treatment.
A pharmacist intervention on asthma control 1353management. The identification of uncontrolled patients
through health initiatives in different settings would allow
targeting asthma management strategies and probably
reducing asthma-related costs over time.
The intervention delivered to patients allocated to the
IG was effective, individualized and tailored to the pa-
tients’ current asthma control, following GEMA recom-
mendations. Adherence education was provided using
different strategies according to the kind of non-adherence
identified in the patient. The intervention was individu-
alised, taking into account specific barriers to medication
adherence, using validated tools for patients presenting
intentional non-adherence. This allowed the assessment of
necessity beliefs and concerns about asthma treatment and
effectively addressed them. Inhaler training was delivered
using written and verbal counselling plus physical demon-
stration (proven to be the most effective way of delivering
such education [36]), improving the percentage of patientsTable 5 Proportion of patients with incorrect performance of s
Turbuhaler inhaler technique step IG (n Z
1 Unscrew and lift off the cover 1 (0.5)
2 Hold the inhaler upright 6 (3.2)
3 Twist the red grip fully to the right as far as
it will go and twist it back again to the left.
A “click” will be heard
2 (1.1)
4 Breathe out gently taking care not to breathe
into the Turbuhaler
20 (10.8
5 Place mouthpiece between teeth and lips 9 (4.8)
6 Inhale forcefully and deeply 12 (6.5)
7 Remove the inhaler from the mouth, hold
breath for 8 s and exhale away from the
mouthpiece
14 (7.5)
8 If further doses are needed wait 30 s and
repeat steps from 2 to 7c
4 (6.0)
9 Replace white cap 3 (1.6)
10 Rinse mouth with water. Do not swallow 9 (4.8)
a For intra-group comparisons between baseline and end point (McN
b For comparisons between groups (ChieSquare test).
c This step was assessed in those patients prescribed with two cons
d McNemar test was not calculated since at least one of the varia
constant.performing correct inhaler technique. As medication
adherence and inhaler technique are both critical issues for
successful asthma management, their improvement prob-
ably contributed to the enhancement of asthma control in
30.1% of patients allocated in the IG. Unfortunately,
neither assessment nor training on inhaler technique is
regularly being performed in many clinical settings,
increasing the risk of misuse of inhaler devices [10].
Nevertheless at the end of the study there still were non-
adherent patients (21.5%) and patients failing to use the
inhaler device correctly (24.2%). Whether these issues in
association with other factors, such as smoking status or
exposure to triggers, may have contributed to 41.9% of
patients failing to achieve good asthma control is unknown.
Some limitations of this study must be mentioned. Firstly,
only patients treated with Symbicort were included in the
study; therefore, our sample may not be representative
of the whole asthma population. Secondly, significantteps for Turbuhaler inhaler technique at final visit.
186) p Valuea CG (n Z 150) p Valuea p Valueb
1.000 0 (0.0) d 0.368
<0.001 34 (22.7) 0.076 <0.001
<0.001 6 (4.0) 0.035 0.080
) <0.001 37 (24.7) <0.001 0.001
0.001 10 (6.7) <0.001 0.471
<0.001 20 (13.3) 0.481 0.033
<0.001 31 (20.7) <0.001 <0.001
<0.001 14 (26.4) 0.012 0.002
0.004 8 (5.3) 1.000 0.057
<0.001 36 (24.0) <0.001 <0.001
emar test).
ecutive inhalations (120 patients: CG Z 53; IG Z 67).
bles used for the calculation of measures of association was a
1354 V. Garcı´a-Ca´rdenas et al.differences between study groups were found at baseline in
mean number of anti-asthmatic drugs and percentage of
patients living in an urban area. Although patients had
similar ACQ scores at baseline, when categorized according
to their level of asthma control, significant differences were
also observed. This concern was controlled for by adjusting
the statistical analysis to take these baseline differences
into account. Finally, since patient’s outcomes were ach-
ieved after a 6-month intervention, sustainability of these
results on a longer term follow-up cannot be assured.
In conclusion, asthma represents a worldwide problem
and public health initiatives are essential to encourage
asthma education for patients and healthcare providers.
The AFasma study focused on the important outcomes
of asthma management, and showed that through the
designed intervention, community pharmacists can in-
crease controlled asthma patients compared to usual care.
Although the intervention delivered seemed to be
compatible with the pharmacists’ daily practice, additional
research would be needed to define the core issues for a
future implementation of the service in a community
pharmacy setting.
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